NCT02860000View on ClinicalTrials.gov

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

January 10, 2022

Study Completion Date

December 31, 2026

Conditions
Estrogen Receptor StatusHER2/Neu NegativeInvasive Breast CarcinomaPostmenopausalStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

Alisertib

Given PO

DRUG

Fulvestrant

Given IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (8)

10461

Montefiore Medical Center, The Bronx

19104

Hospital of the University of Pennsylvania, Philadelphia

20007

Georgetown University Medical Center, Washington D.C.

27710

Duke University Medical Center, Durham

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER